{"id":"W4415940884","doi":"10.1016/j.annonc.2025.08.2130","title":"1500P SOLARIS: A phase-II open-label Study of pembrOlizumab and Lenvatinib in patients with Advanced stage hepatocellular carcinoma who are Refractory to atezolizumab and bevacizumab/ IO-baSed therapy (IKF t-037 trial)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Deutsche Forschungsgemeinschaft","keywords":"Lenvatinib; Pembrolizumab; Atezolizumab; Refractory (planetary science); Nivolumab; Regorafenib; Concomitant; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00117579,0.001211827,0.002036914,0.0003665721,0.0002793837,0.001305984,0.000770382,0.001005095,0.006019335],"category_scores_gemma":[0.0008070036,0.0005220795,0.001810328,0.0003712033,0.0008857538,0.001207811,0.000373464,0.003667301,0.001373576],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001008596,"about_ca_system_score_gemma":0.001280049,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001256751,"about_ca_topic_score_gemma":0.003657352,"domain_scores_codex":[0.9997295,0.0001154385,0.00001074297,0.0000501275,0.00002737422,0.0000668093],"domain_scores_gemma":[0.9996181,0.00006450154,0.00008260004,0.0000295438,0.00002017894,0.0001851331],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8434547,0.01743766,0.004149535,0.001091604,0.003347571,0.0001342227,0.0001734291,0.002330792,0.01649749,0.0005848657,0.007025082,0.1037732],"study_design_scores_gemma":[0.9140708,0.07361794,0.006557083,0.00004038224,0.0008904638,0.0001446297,0.00006097112,0.001019302,0.001026291,0.0003344045,0.002213061,0.00002473447],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9878812,0.003623195,0.0005786078,0.001092083,0.0003113901,0.001347408,0.001867817,0.0001898609,0.003108372],"genre_scores_gemma":[0.982195,0.003786465,0.001727956,0.001530992,0.0002816077,0.001886951,0.003788291,0.00005740751,0.004745387],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006019335,"threshold_uncertainty_score":0.02013665,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1386399390713997,"score_gpt":0.3816218250340124,"score_spread":0.2429818859626127,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}